Corrigendum to “Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan” [Lung Cancer, 129 (March)(2019)55–62](S0169500219300212)(10.1016/j.lungcan.2019.01.005)

Satoshi Watanabe, Hiroshige Yoshioka, Hiroshi Sakai, Katsuyuki Hotta, Mitsuhiro Takenoyama, Kazuhiko Yamada, Shunichi Sugawara, Yuichi Takiguchi, Yukio Hosomi, Keisuke Tomii, Seiji Niho, Nobuyuki Yamamoto, Makoto Nishio, Yuichiro Ohe, Terufumi Kato, Toshiaki Takahashi, Ami Kamada, Kazumi Suzukawa, Yukie Omori, Sotaro EnatsuKazuhiko Nakagawa, Tomohide Tamura

Research output: Contribution to journalComment/debatepeer-review

1 Citation (Scopus)

Fingerprint

Dive into the research topics of 'Corrigendum to “Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan” [Lung Cancer, 129 (March)(2019)55–62](S0169500219300212)(10.1016/j.lungcan.2019.01.005)'. Together they form a unique fingerprint.

Medicine & Life Sciences